好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Online CME Program Demonstrates Differential Pre-education Awareness of Anti-amyloid Therapies in Alzheimer’s Disease Among Neurologists and a Strong 好色先生al Effect Across Topics
Aging, Dementia, and Behavioral Neurology
P1 - Poster Session 1 (8:00 AM-9:00 AM)
12-009
A study was undertaken to evaluate the impact of an online CME-certified program on identifying treatment goals for early stages of AD and patient selection factors for AATs among neurologists.    
The clinical adoption of anti-amyloid therapies (AATs) require substantial modifications to how Alzheimer's disease (AD) is managed in practice. Since these medication are a recent addition to the therapeutic landscape in AD, neurologists who are currently in practice may not be aware of the practical consideration related to the use of AATs.

The online CME activity consisted of a 30-minute video discussion between 1 dementia expert,  1 neuroradiologist, 1 geriatrician, and 1 patient advocate. 好色先生al effect was assessed by comparing responses to four identical questions presented before and directly after exposure to the intervention.  A paired samples t-test assessed the overall average number of correct responses and a McNemar’s test identified significant between pre- and post-differences in question responses. The educational effect size was calculated by Cohen’s d. Data were collected between March 2025 and June 2025.

Participation in the CME intervention resulted in a large educational effect size among neurologists (n=113; d=.88; p<0.001). Significant (P <.05) pre- vs post-educational improvements were demonstrated on the following: goals of treating early AD; patient selection factors for AATs; contraindications for AATs. Between 64%-72% correctly answered question on goals of treatment and patient selection factors prior to the intervention. Only 22% correctly answered a question on contraindications for AAT use prior to the intervention.  After participating in the intervention, 37% reported an increase in their confidence to speak with patients and families about the benefits and risks of AATs.

The results indicated that the CME-certified 30-minute video discussion between experts improved the knowledge of neurologists regarding the appropriate use of AATs. Neurologists would benefit from future education that prioritizes contraindications for AATs. 
Authors/Disclosures
Austin Baiardi, NA
PRESENTER
Mr. Baiardi has nothing to disclose.
Thomas Finnegan, Jr., PhD (Medscape 好色先生) Dr. Finnegan has nothing to disclose.
Frances McFarland Frances McFarland has nothing to disclose.